A multi-award winning regional contract research organization (CRO)
Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific Region.
Solutions we offer
Where We operate
- North America
- 约1,800名调查员 参与了至少5项研究
Novotech has three customer facing offices
on both the East Coast and West Coast.
- Dr. John Moller
Chief Executive Officer, Novotech CRO
Novotech Partners with National Taiwan University Hospital (NTUH) to Support Biotech Clinical Trials
Taipei, Taiwan – Asia-Pacific specialist CRO Novotech announced today that leading National Taiwan University Hospital (
Novotech Wins Australian-Korean Business Excellence Award 2020
Seoul, South Korea - Asia-Pacific specialist CRO Novotech has won the Australian-Korean Business Awards
Asia-Pacific has record year for clinical trials according to Novotech
13 January 2020
Asia: Preferred Destination for Clinical Trials
The clinical trials process is complicated and time-consuming, requiring substantial investment. Biotechnology and pharmaceutical companies in the United States (US) and Europe face escalating clinical trial costs and challenges in both recruiting and retaining patients. Additionally, companies have to navigate through complex regulatory processes.
Australia: Preferred Destination for Early Phase Clinical Trials
The clinical trials process is complex. It requires substantial investment and skilled human re-sources, and involves risks, not least, the navigation of complex regulatory processes. To over-come these challenges, small biotechnology companies outsource their early phase clinical studies to contract research organizations (CROs). This white paper highlights research on why Australia continues to be a hub for early phase clinical trials.
Our Latest Reports
Accelerating Genetic Therapy Clinical Trials in Asia-Pacific
A growing number of biotechnology companies, both in the West and in Asia, are specializing in gene therapies and other regenerative treatments boosted by the approval of the first genetic therapy agent (tisagenlecleusel) by the FDA in 2017.
Accelerating Immunotherapy Clinical Trials in Asia-Pacific
Over 600 sites across Asia-Pacific have been involved in the clinical development of now approved IO drugs, and hundreds more are experienced in managing clinical trials with immunotherapies for both monotherapy and combination therapies.
Orphan drug trials accelerating in Asia Pacific
We have observed an unprecedented effort in the clinical development of Orphan drugs in the recent years. In fact, in 2018, the majority of new drugs approved by the FDA and EMA were Orphan medicines.
The objective of this report is to describe the Orphan drug development landscape and explain how the positioning of the Asia region has been evolving in the global picture.
Overview of Lung cancer landscape in Asia
Lung cancer is one of the most common malignancies in the world, representing about 1.6 million cases annually and over 10% of all new cancers. The most well-known risk factor for lung cancer is cigarette smoking which has become endemic in Asia.